Latest News and Press Releases

RENO, Nev., April 10, 2025 (GLOBE NEWSWIRE) -- ITS Logistics today released the April forecast for the ITS Logistics US Port/Rail Ramp Freight Index. This month, the index reveals that frontloading...

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals

Petaluma, CA, Dec. 30, 2024 (GLOBE NEWSWIRE) -- American Ratings Corporation (ARC), creator of Diamond Certified Resource, has announced the relaunch of its HealthSafety Qualified Resource website....

Washington, DC, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Article: https://thinkcarebelieve.blog/2024/12/02/the-hunter-biden-pardon-and-us-biolabs-in-ukraine/ ThinkCareBelieve...

Milwaukee, Wis., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services’ (HHS) Risk Less. Do More. campaign is partnering with the HBCU Tailgate Tour to increase...

The politicized response to Covid included a war on the use of ivermectin. Studies have conflicting results. The issue is at a stalemate.

COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE DES RESULTATS POSITIFS DE SON ETUDE DE PHASE 2 EVALUANT LE MASITINIB DANS LA COVID-19 Paris, 8 juillet 2024, 8h AB Science SA (Euronext - FR0010557264 - AB)...

PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the...

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...